Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7.
Authors:
Open Access
- 1 September 2009
- journal article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 42 (9) , 854-862
Abstract
The aim of the present study was to determine the effect of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and adriamycin (ADM) on the human breast cancer cell line MCF-7 and to identify potential mechanisms of apoptosis. Cell viability was analyzed by the MTT assay and the synergistic effect was assessed by the Webb coefficient. Apoptosis was quantified using the annexin V-FITC and propidium iodide staining flow cytometry. The mRNA expression of TRAIL receptors was measured by RT-PCR. Changes in the quantities of Bax and caspase-9 proteins were determined by Western blot. MCF-7 cells were relatively resistant to TRAIL (IC50 >10 microg/mL), while MCF-7 cells were sensitive to ADM (IC50 <10 microg/mL). A subtoxic concentration of ADM (0.5 microg/mL) combined with 0.1, 1, or 10 microg/mL TRAIL had a synergistic cytotoxic effect on MCF-7 cells, which was more marked with the combination of TRAIL (0.1 microg/mL) and ADM (0.5 microg/mL). In addition, the combined treatment with TRAIL and ADM significantly increased cell apoptosis from 9.8% (TRAIL) or 17% (ADM) to 38.7%, resulting in a synergistic apoptotic effect, which is proposed to be mediated by up-regulation of DR4 and DR5 mRNA expression and increased expression of Bax and caspase-9 proteins. These results suggest that the combination of TRAIL and ADM might be a promising therapy for breast cancer.Keywords
This publication has 27 references indexed in Scilit:
- Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancerAnti-Cancer Drugs, 2008
- Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatmentApoptosis, 2008
- Pretreatment of docetaxel enhances TRAIL‐mediated apoptosis in prostate cancer cellsJournal of Cellular Biochemistry, 2008
- Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cellsAnti-Cancer Drugs, 2007
- The clinical trail of TRAILEuropean Journal of Cancer, 2006
- Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and ApoptosisScience, 2004
- Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cellsInternational Journal of Cancer, 2003
- Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivoOncogene, 2001
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Quercetin: Synergistic action with carboxyamidotriazole in human breast carcinoma cellsLife Sciences, 1995